Latest & greatest articles for adhd

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on adhd or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on adhd and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

ADHD

ADHD (or Attention deficit hyperactivity disorder) is a neurodevelopmental type mental disorder. It is characterised two main categories of two types of behavioural problems:

  • inattentiveness
  • hyperactivity and impulsiveness

Most people with ADHD have problems that fall into both categories, but it doesn’t have to be the case. If a person just has inattentiveness it is referred to as attention deficit disorder (ADD).

Methylphenidate is a commonly used medication used to treat patients suffering from attention-deficit hyperactivity disorder. Methylphenidate is part of a group of drugs known as stimulants. Central nervous system stimulants help change the amounts of natural substances in the brain. But it is not the only intervention; others include Bupropion, exercise and CBT (Cognitive behavioural therapy).

Extensive ADHD research and case studies have been carried out over numerous years. Trip has unrivalled coverage of the evidence base including systematic reviews, clinical trials, clinical guidelines and case studies.

Studies are ongoing to assess the safety and effectiveness of stimulants used on children with ADHD and intellectual disabilities as well as in other populations and other interventions. Trip also includes ongoing controlled trials and ongoing systematic reviews (via the PROSPERO database).

Top results for adhd

41. National clinical guideline for the assessment and treatment of ADHD in children and adolescents

National clinical guideline for the assessment and treatment of ADHD in children and adolescents NATIONAL CLINICAL GUIDELINE FOR THE ASSESSMENT? AND TREATMENT OF ADHD IN CHILDREN AND ADOLESCENTS – WITH A FOCUS ON THE DIAGNOSES “DISTURBANCE OF ACTIVITY AND ATTENTION” AND “ATTENTION DEFICIT DISORDER WITHOUT HYPERACTIVITY” ACCORDING TO ICD-10 Quick guide National clinical guideline for the assessment and treatment of ADHD in children and adolescents Published by the Danish Health Authority, June (...) 2016 Assessment v It is good practice to ensure that a diagnostic standard assessment for ADHD in children and adolescents aged 6-18 years is interdisciplinary and cross-sectorial and includes the following sub-elements: - Clinical interview including medical history - Standardised rating scales or questionnaires - Collection of information on and potential observation if desired of the child/the adolescent in everyday life - Somatic examination by a physician/medical doctor - Psychological

Danish National Clinical Guidelines2016

42. Practice advisory: the utility of eeg theta/beta power ratio in adhd diagnosis

Practice advisory: the utility of eeg theta/beta power ratio in adhd diagnosis Practice advisory: The utility of EEG theta/beta power ratio in ADHD diagnosis | Neurology Advertisement Search for this keyword Main menu User menu Search Search for this keyword The most widely read and highly cited peer-reviewed neurology journal Share November 29, 2016 ; 87 (22) Special Article Practice advisory: The utility of EEG theta/beta power ratio in ADHD diagnosis Report of the Guideline Development (...) .), University of California at Los Angeles. Practice advisory: The utility of EEG theta/beta power ratio in ADHD diagnosis David Gloss , Jay K. Varma , Tamara Pringsheim , Marc R. Nuwer Neurology Nov 2016, 87 (22) 2375-2379; DOI: 10.1212/WNL.0000000000003265 Citation Manager Formats Downloads 1955 Share Abstract Objective: To evaluate the evidence for EEG theta/beta power ratio for diagnosing, or helping to diagnose, attention-deficit/hyperactivity disorder (ADHD). Methods: We identified relevant studies

American Academy of Neurology2016

43. Atomoxetine (Strattera) - treatment of attention-deficit/hyperactivity disorder (ADHD)

Atomoxetine (Strattera) - treatment of attention-deficit/hyperactivity disorder (ADHD) Published 07 December 2015 Product Update atomoxetine oral solution 4mg/mL (Strattera ® ) SMC No. (1107/15) Eli Lilly and Company Limited 06 November 2015 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises NHS Boards and Area Drug and Therapeutic Committees (ADTCs) on its use in NHS Scotland. The advice is summarised as follows: ADVICE: following (...) an abbreviated submission atomoxetine oral solution (Strattera ® ) is accepted for restricted use within NHS Scotland. Indication under review: treatment of attention-deficit/hyperactivity disorder (ADHD) in children of 6 years and older, in adolescents and in adults as part of a comprehensive treatment programme. Treatment must be initiated by a specialist in the treatment of ADHD, such as a paediatrician, child/adolescent psychiatrist, or psychiatrist. Diagnosis should be made according to current DSM

Scottish Medicines Consortium2015

44. Lisdexamfetamine dimesylate (Elvanse Adult) - as part of a comprehensive treatment programme for attention deficit/hyperactivity disorder (ADHD) in adults.

Lisdexamfetamine dimesylate (Elvanse Adult) - as part of a comprehensive treatment programme for attention deficit/hyperactivity disorder (ADHD) in adults. Final Appraisal Recommendation Advice No: 2615 – September 2015 Lisdexamfetamine dimesylate (Elvanse Adult ® ? ) 30 mg, 50 mg and 70 mg hard capsules Submission by Shire Pharmaceuticals Ltd In reaching the above recommendation AWMSG has taken account of the appraisal documentation prepared by the AWMSG Secretariat (reference number 2534 (...) the whole recommendation being quoted in full and cited as: All Wales Medicines Strategy Group. Final Appraisal Recommendation – 2615: Lisdexamfetamine dimesylate (Elvanse Adult ® ? ) 30 mg, 50 mg and 70 mg hard capsules. September 2015. Recommendation of AWMSG Lisdexamfetamine dimesylate (Elvanse Adult ® ? ) is recommended as an option for use within NHS Wales as part of a comprehensive treatment programme for attention deficit/hyperactivity disorder (ADHD) in adults.

All Wales Medicines Strategy Group2015

45. ADHD Medication Switching for Patients with Aggression or Mood Changes Secondary to Current Medication: Review of Clinical Effectiveness and Guidelines

ADHD Medication Switching for Patients with Aggression or Mood Changes Secondary to Current Medication: Review of Clinical Effectiveness and Guidelines ADHD Medication Switching for Patients with Aggression or Mood Changes Secondary to Current Medication: Review of Clinical Effectiveness and Guidelines | CADTH.ca Find the information you need ADHD Medication Switching for Patients with Aggression or Mood Changes Secondary to Current Medication: Review of Clinical Effectiveness and Guidelines (...) ADHD Medication Switching for Patients with Aggression or Mood Changes Secondary to Current Medication: Review of Clinical Effectiveness and Guidelines Published on: September 15, 2015 Project Number: RC0701-000 Product Line: Research Type: Drug Report Type: Summary with Critical Appraisal Result type: Report Question What is the clinical effectiveness and safety of switching to another ADHD medication for patients who experience aggression or mood changes secondary to therapy with methylphenidate

Canadian Agency for Drugs and Technologies in Health - Rapid Review2015

46. Dosage Delivery of ADHD Medications for Patients with Swallowing Difficulties: Guidelines

Dosage Delivery of ADHD Medications for Patients with Swallowing Difficulties: Guidelines Dosage Delivery of ADHD Medications for Patients with Swallowing Difficulties: Guidelines | CADTH.ca Find the information you need Dosage Delivery of ADHD Medications for Patients with Swallowing Difficulties: Guidelines Dosage Delivery of ADHD Medications for Patients with Swallowing Difficulties: Guidelines Published on: September 3, 2015 Project Number: RB0905-000 Product Line: Research Type: Drug (...) Report Type: Summary of Abstracts Result type: Report Question What is the clinical evidence regarding methods of dosage delivery of attention deficit hyperactivity disorder (ADHD) medications to patients with swallowing difficulties? What are the evidence-based guidelines regarding method of dosage delivery of ADHD medications to patients with swallowing difficulties? Key Message One evidence-based guideline was identified regarding methods of dosage delivery of ADHD medications to patients

Canadian Agency for Drugs and Technologies in Health - Rapid Review2015

47. Lisdexamfetamine dimesylate (Elvanse Adult) - attention deficit/hyperactivity disorder (ADHD) in adults

Lisdexamfetamine dimesylate (Elvanse Adult) - attention deficit/hyperactivity disorder (ADHD) in adults

Scottish Medicines Consortium2015

48. Non-pharmacological interventions for attention-deficit/hyperactivity disorder (ADHD) delivered in school settings: systematic reviews of quantitative and qualitative research

Non-pharmacological interventions for attention-deficit/hyperactivity disorder (ADHD) delivered in school settings: systematic reviews of quantitative and qualitative research Non-pharmacological interventions for attention-deficit/hyperactivity disorder (ADHD)delivered in school settings: systematic reviews of quantitative and qualitative research Journals Library An error occurred retrieving content to display, please try again. >> >> >> Page Not Found Page not found (404) Sorry - the page (...) you requested could not be found. Please choose a page from the navigation or try a website search above to find the information you need. >> >> >> >> Issue {{metadata .Issue }} Toolkit 1)"> 0)"> {{metadata.Title}} {{metadata.Headline}} The study found some beneficial effects of non-pharmacological interventions for attention-deficit/hyperactivity disorder used in school settings, but substantial heterogeneity in effect sizes was seen across studies. The qualitative reviews demonstrate

NIHR HTA programme2015 Full Text: Link to full Text with Trip Pro

49. Medical augmentation of labor and the risk of ADHD in offspring: a population-based study

Medical augmentation of labor and the risk of ADHD in offspring: a population-based study 25667242 2015 03 03 2015 04 28 2015 03 03 1098-4275 135 3 2015 Mar Pediatrics Pediatrics Medical augmentation of labor and the risk of ADHD in offspring: a population-based study. e672-7 10.1542/peds.2014-1542 Oxytocin for labor augmentation is widely used in obstetric care in Western countries. Two recent, smaller studies found opposing results regarding the association between prenatal exposure (...) to oxytocin for labor augmentation and attention-deficit/hyperactivity disorder (ADHD). In Denmark, oxytocin is the medication used for nearly all medical augmentations of labor, and we examined the association between medical augmentation of labor and ADHD in a large cohort study based on national register data. All singletons born after spontaneous onset of labor in Denmark between 2000 and 2008 (N = 546 146) were included in the study. Data from the Danish Medical Birth Registry on medical augmentation

EvidenceUpdates2015 Full Text: Link to full Text with Trip Pro

50. What is the most effective therapy for childhood attention deficit hyperactivity disorder (ADHD)?

What is the most effective therapy for childhood attention deficit hyperactivity disorder (ADHD)? What is the most effective therapy for childhood attention deficit hyperactivity disorder (ADHD)? Toggle navigation Shared more. Cited more. Safe forever. Toggle navigation View Item JavaScript is disabled for your browser. Some features of this site may not work without it. Search MOspace This Collection Browse Statistics What is the most effective therapy for childhood (...) attention deficit hyperactivity disorder (ADHD)? View/ Open Date 2015-02 Format Metadata Abstract What is the most effective therapy for childhood attention deficit hyperactivity disorder (ADHD)? Bottom line: Osmotically released methylphenidate is slightly more effective than atomoxetine for treating the symptoms of ADHD, whereas immediate-release methylphenidate shows no benefit over atomoxetine (SOR: B, metaanalysis of RCTs with significant heterogeneity). Atomoxetine is more effective than placebo. The addition of clonidine

Evidence Based Practice 2015

51. Miscellaneous: Telepsychiatry intervention is better for ADHD symptoms than usual treatment augmented by telemedicine consultation

Miscellaneous: Telepsychiatry intervention is better for ADHD symptoms than usual treatment augmented by telemedicine consultation Telepsychiatry intervention is better for ADHD symptoms than usual treatment augmented by telemedicine consultation | Evidence-Based Mental Health This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password (...) * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Telepsychiatry intervention is better for ADHD symptoms than usual treatment augmented by telemedicine consultation Article Text Electronic pages Miscellaneous Telepsychiatry intervention is better for ADHD symptoms than usual treatment augmented

Evidence-Based Mental Health2015

52. ADHD: medication and society

ADHD: medication and society ADHD: medication and society ADHD: medication and society Health Council of the Netherlands Record Status This is a bibliographic record of a published health technology assessment. No evaluation of the quality of this assessment has been made for the HTA database. Citation Health Council of the Netherlands. ADHD: medication and society. The Hague: Health Council of the Netherlands Gezondheidsraad (GR). 2014/19. 2014 Final publication URL Indexing Status Subject (...) indexing assigned by CRD MeSH Attention Deficit Disorder with Hyperactivitys Language Published English Country of organisation Netherlands English summary An English language summary is available. Address for correspondence Postbus 16052, 2500 BB Den Haag, The Netherlands. Tel: +31 70 340 7520;Fax: +31 70 340 7523 Email: info@gr.nl AccessionNumber 32014000924 Date abstract record published 23/07/2014 Health Technology Assessment (HTA) database Copyright © 2017 Health Council of the Netherlands

Health Technology Assessment (HTA) Database.2014

53. Nonpharmacological interventions for ADHD: systematic review and meta-analyses of randomized controlled trials of dietary and psychological treatments

Nonpharmacological interventions for ADHD: systematic review and meta-analyses of randomized controlled trials of dietary and psychological treatments Nonpharmacological interventions for ADHD: systematic review and meta-analyses of randomized controlled trials of dietary and psychological treatments Nonpharmacological interventions for ADHD: systematic review and meta-analyses of randomized controlled trials of dietary and psychological treatments Sonuga-Barke EJ, Brandeis D, Cortese S, Daley (...) D, Ferrin M, Holtmann M, Stevenson J, Danckaerts M, van der Oord S, Dopfner M, Dittmann RW, Simonoff E, Zuddas A, Banaschewski T, Buitelaar J, Coghill D, Hollis C, Konofal E, Lecendreux M, Wong IC, Sergeant J, European ADHD Guidelines Group CRD summary Free fatty acid supplementation and artificial food colour exclusions appeared to have benefits for attention deficit hyperactivity disorder (ADHD); the evidence for behavioural interventions was limited. The authors’ conclusions seem reliable

DARE.2014

54. Management of ADHD in preschool-aged children

Management of ADHD in preschool-aged children Management of ADHD in preschool-aged children Toggle navigation Shared more. Cited more. Safe forever. Toggle navigation View Item JavaScript is disabled for your browser. Some features of this site may not work without it. Search MOspace This Collection Browse Statistics Management of ADHD in preschool-aged children View/ Open Date 2013-09 Format Metadata Abstract Behavior therapy interventions, such as parent training, are first-line treatment (...) for ADHD in preschool-aged children (three to five years of age). (Strength of Recommendation [SOR]: B, based on a systematic review of a small number of heterogeneous randomized controlled trials [RCTs].) Medication is an option for children with moderate to severe ADHD if behavior therapy has not been effective and if the benefits outweigh the harms. (SOR: B, based on a systematic review of a small number of heterogeneous RCTs.) Alternative therapies, such as elimination diets, have limited evidence

Clinical Inquiries2014

55. Atomoxetine (Strattera) - adults with attention deficit hyperactivity disorder (ADHD)

Atomoxetine (Strattera) - adults with attention deficit hyperactivity disorder (ADHD) All Wales Medicines Strategy Group (AWMSG) - atomoxetine (Strattera) | | Appraisal information Search and reports atomoxetine (Strattera®) Reference No. 1361 Publication date: 27/02/2014 Last review date: 01/12/2016 Appraisal information atomoxetine (Strattera®) 10 mg capsule atomoxetine (Strattera®) 18 mg capsule atomoxetine (Strattera®) 25 mg capsule atomoxetine (Strattera®) 40 mg capsule atomoxetine (...) NHS Wales for the initiation of treatment in adults with attention deficit hyperactivity disorder (ADHD). Treatment must be initiated by a specialist in the treatment of ADHD, such as a paediatrician, child/adolescent psychiatrist, or psychiatrist. Diagnosis should be made according to current Diagnostic and Statistical Manual of Mental Disorders (DSM) criteria or the guidelines in International Classification of Mental and Behavioural Disorders (ICD). In adults, the presence of symptoms of ADHD

All Wales Medicines Strategy Group2014

56. Review: recommendations for the assessment and management of sleep disorders in ADHD

Review: recommendations for the assessment and management of sleep disorders in ADHD Review: recommendations for the assessment and management of sleep disorders in ADHD | Evidence-Based Mental Health This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword (...) Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Review: recommendations for the assessment and management of sleep disorders in ADHD Article Text Outcomes Review: recommendations for the assessment and management of sleep disorders in ADHD Statistics from Altmetric.com No Altmetric data available for this article. Question Question: What evidence-based or consensus-based

Evidence-Based Mental Health2014

57. Review: no evidence that stimulant medication for ADHD influences lifetime risk of substance use or dependence

Review: no evidence that stimulant medication for ADHD influences lifetime risk of substance use or dependence Review: no evidence that stimulant medication for ADHD influences lifetime risk of substance use or dependence | Evidence-Based Mental Health This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password (...) ? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Review: no evidence that stimulant medication for ADHD influences lifetime risk of substance use or dependence Article Text Causes Review: no evidence that stimulant medication for ADHD influences lifetime risk of substance use or dependence Statistics from Altmetric.com No Altmetric

Evidence-Based Mental Health2014

58. Atomoxetine is a second-line medication treatment option for ADHD

Atomoxetine is a second-line medication treatment option for ADHD Atomoxetine is a second-line medication treatment option for ADHD | Evidence-Based Mental Health This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username (...) and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Atomoxetine is a second-line medication treatment option for ADHD Article Text Pharmacological interventions Atomoxetine is a second-line medication treatment option for ADHD Jaswinder K Ghuman 1 , Shari L Hutchison 2 Statistics from Altmetric.com No Altmetric data available for this article. What is already known on this topic? Atomoxetine is a non-stimulant that has

Evidence-Based Mental Health2014

59. Medication reduces crash risk among men with ADHD

Medication reduces crash risk among men with ADHD Medication reduces crash risk among men with ADHD | Evidence-Based Mental Health This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts (...) OR managers of institutional accounts Username * Password * your user name or password? You are here Medication reduces crash risk among men with ADHD Article Text Causes and risk factors Medication reduces crash risk among men with ADHD Flaura Koplin Winston 1 , Daniel Romer 2 Statistics from Altmetric.com No Altmetric data available for this article. What is already known on this topic? Safe driving requires ‘situation awareness’, a combined implementation of skills and traits that include attending

Evidence-Based Mental Health2014

60. ADHD, Attention Deficit Hyperactivity Disorder in Primary Care for School-Age Children and Adolescents

ADHD, Attention Deficit Hyperactivity Disorder in Primary Care for School-Age Children and Adolescents 1 ICSI has endorsed with qualifications the American Academy of Pediatrics (AAP's) guideline, ADHD: Clinical Practice Guideline for the Diagnosis, Evaluation and Treatment of Attention-Deficit/Hyperactivity Disorder in Children and Adolescents, and Supplement. Both have been reviewed by the 2014 ICSI ADHD work group, utilizing the ICSI Endorsement Process: C. Dobie, W. Donald, K.Elhai, J (...) . Hoffman-Jecha, J Huxsahl, R. Karasov, C. Kippes, C. Myers, J. Peters, L. Steiner, M. Wild Crea. Additional work group information, including the members declared conflicts of interest. Access this guideline and supplement through the links below: American Academy of Pediatrics – ADHD: Clinical Practice Guideline for the Diagnosis, Evaluation, and Treatment of Attention- Deficit/Hyperactivity Disorder in Children and Adolescents American Academy of Pediatrics – Implementing the Key Action Statements

Institute for Clinical Systems Improvement2014